Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
收藏DataCite Commons2025-07-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00010849/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
提供机构：
Vivli
创建时间：
2024-12-06
